

Statement of Withdrawal of the Study
Sponsor : Incyte Corporation
Study # : INCB 39110-210 (EudraCT#2018-004491-35)
Product: INCB039110
Study Title: A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
Phase: II
Study Period: NA
Centres: NA
Number of Subjects: 0
Publications: NA
Statement on withdrawal of the study: This study was prematurely ended prior to the start of enrollment by the Sponsor. Globally no subjects were enrolled into the study. Therefore no results / data are available.